Robert Bristow is the Director of Manchester Cancer Research Centre and Director of CRUK Major Centre. He was previously a Clinician-Scientist and Professor within the Departments of Radiation Oncology and Medical Biophysics at the University of Toronto and a Senior Scientist at the Princess Margaret Cancer Centre. His primary research interests are in tumour hypoxia, DNA damage signalling and DNA repair in tumours, and the genomics of prostate cancer progression and cancer treatment response. He is particularly interested in novel clinical trials that intensify cancer therapy to prostate cancer patients whose tumours harbour aggressive genetic changes and hypoxic sub-regions. He has over 300 published papers and book chapters. He is twice a Canadian Foundation for Innovation (CFI) awardee. He was made a Canadian Cancer Society Research Scientist in 2004, an ESTRO Honorary Fellow in 2011 and a Fellow of the Academy of Medical Sciences in 2019.

Nat Commun. 2021 Nov 25;12(1):6893. doi: 10.1038/s41467-021-27223-6.
Nat Commun. 2021 Oct 29;12(1):6248. doi: 10.1038/s41467-021-26489-0.
Cancer Res. 2021 Dec 1;81(23):5833-5848. doi: 10.1158/0008-5472.CAN-21-2056. Epub 2021 Oct 12.
Lancet. 2021 Sep 18;398(10305):1075-1090. doi: 10.1016/S0140-6736(21)00950-8. Epub 2021 Aug 6